Idorsia (Debt Restructuring)
Funding Details
- Awarder
- Inbox
- Date Award
- May 18, 2025
- Vertical
- Biopharmaceuticals
- Funding URL
- View Funding Page
- Funding Amount:
- $150,000,000
Company Info
- Traction
- Sales of QUVIVIQ (daridorexant) reached CHF 61 million, with projections of approximately CHF 110 million in 2025.
- Revenue Amount
- $113,000,000
- Company Description
- The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients.
- Market
- Healthcare
- Location
- Allschwil, Switzerland